Drug Trial Radar · NCT00758498
Study of the Effect of Armodafinil Treatment in Healthy Subjects With Excessive Sleepiness Associated With Jet Lag Disorder
Last checked: Nov 20, 2026Latest source record: Jul 19, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
427
Actual
Start
Sep 2008
Primary completion
Feb 2009
Study completion Feb 2009
Sponsor
- Lead sponsor
- CephalonIndustry
- Sponsor type
- Industry
- First posted
- Sep 25, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo-controlled, parallel-group study of armodafinil and placebo treatment in healthy subjects with excessive sleepiness associated with jet lag disorder.
Conditions
- Excessive Sleepiness
Interventions
armodafinilDrug
50 mg/day orally, once daily in the morning for 3 days
armodafinilDrug
150 mg/day orally, once daily in the morning for 3 days
placeboDrug
placebo tablets, once daily in the morning for 3 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Sleep Latency (Minutes) From the Multiple Sleep Latency Test (MSLT)- Average of Four Scheduled Naps Across Days 1 and 2Time frame: Days 1 and 2
- Average of Patient Global Impression of Severity (PGI-S) of General Condition Ratings Across Days 1 and 2Time frame: Days 1 and 2
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Neurotrials Research, Inc.
Atlanta, Georgia
Community Research
Crestview, Kentucky
Clinilabs, Inc.
New York, New York
SleepMed of South Carolina
Columbia, South Carolina
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.